AstraZeneca is working with Oxford University to modify the COVID-19 vaccine to protect against new strains of the virus as public health officials raise concerns about mutations that could make the virus more resistant to the vaccines which is.
LONDON – AstraZeneca said Thursday it is working with Oxford University to modify the COVID-19 vaccine to protect against new strains of the virus as public health officials raise concerns about possible mutations of the virus. make it more sustainable for existing vaccines.
The Anglo-Swedish drug dealer worked with Oxford to develop one of the first COVID-19 vaccines authorized for widespread use. AstraZeneca said it hopes to cut the time needed to cut large quantities of any new vaccine to between six and nine months.
The comments came as Astra-Zeneca reported that net revenue in the fourth quarter rose to $ 1.01 billion from $ 313 million in the same quarter a year earlier. Drug sales increased 11% to $ 7.41 billion, driven by a 24% increase in cancer treatments.
The company raised $ 2 million in revenue from its COVID-19 vaccine, which it has pledged on a nonprofit basis during the pandemic, and said it would begin separate vaccine sales statement starting next quarter.
———